PROVECTUS BIOPHARMACEUTICALS, INC. (OTCMKTS:PVCT) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07.
|
Submission of Matters to a Vote of Security Holders. |
(a) Provectus Biopharmaceuticals, Inc. (the Company) held a
special meeting of stockholders (the Special Meeting) on
November28, 2016.
(b) At the Special Meeting, the Companys stockholders voted on
two proposals. A brief description and tabulation of votes is set
forth below.
Proposal 1. The Companys stockholders approved
and adopted an amendment to our Certificate of Incorporation, as
amended, to increase the number of shares of common stock, par
value, $0.001 per share, that the Company is authorized to issue
from 400,000,000 to 1,000,000,000 shares. There were no broker
non-votes with respect to the proposal.
|
Votes For |
Votes Against |
Votes Abstained |
||
|
142,319,301 |
39,235,538 | 1,055,457 |
Proposal 2. The Companys stockholders did not
approve an amendment to our Certificate of Incorporation, as
amended, to effect a reverse stock split of our common stock at a
ratio of between 1-for-10 and 1-for-50, such ratio to be
determined by our Board of Directors in its discretion. There
were no broker non-votes with respect to the proposal.
|
Votes For |
Votes Against |
Votes Abstained |
||
|
87,543,644 |
91,019,452 | 4,047,200 |
About PROVECTUS BIOPHARMACEUTICALS, INC. (OTCMKTS:PVCT)
Provectus Biopharmaceuticals, Inc. is a development-stage biopharmaceutical company. The Company is engaged in developing pharmaceuticals for oncology and dermatology indications. The Company is focused on developing its prescription drug candidates, PV-10 and PH-10. It is developing PV-10 for treatment of several life threatening cancers, including metastatic melanoma, liver cancer and breast cancer. It is developing PH-10 to provide minimally invasive treatment of chronic severe skin afflictions, such as psoriasis and atopic dermatitis, a type of eczema. In addition to clinical trials, patients enrolled in the expanded access or compassionate use program for PV-10 are also receiving PV-10 treatments for cutaneous and subcutaneous cancer indications. The Company also focuses on over-the-counter (OTC) products and various other non-core technologies. PV-10 is a sterile injectable form of rose bengal disodium (Rose Bengal), for direct injection into tumors. PROVECTUS BIOPHARMACEUTICALS, INC. (OTCMKTS:PVCT) Recent Trading Information
PROVECTUS BIOPHARMACEUTICALS, INC. (OTCMKTS:PVCT) closed its last trading session down -0.0090 at 0.0270 with 1,091,237 shares trading hands.